Neuroprotective effect of treatment with human albumin in permanent focal cerebral ischemia: Histopathology and cortical perfusion studies

Yitao Liu, Ludmila Belayev, Weizhao Zhao, Raul Busto, Andrey Belayev, Myron Ginsberg

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

In recent experimental studies, we demonstrated a highly beneficial neuroprotective effect of moderate- to high-dose human albumin treatment of transient focal cerebral ischemia, but we did not define the effect of albumin therapy in permanent focal cerebral ischemia. In this study, anesthetized Sprague-Dawley rats were subjected to permanent middle cerebral artery occlusion by retrograde insertion of an intraluminal nylon suture coated with poly-L-lysine. Albumin was administered i.v. at 2 h after onset of middle cerebral artery occlusion, in doses of either 1.25 (n = 8) or 2.5 g/kg (n = 6). In a separate group of animals, albumin (2.5 g/kg) was given 1 h after middle cerebral artery occlusion (n = 6). Vehicle-treated rats (n = 6) received 0.9% saline in equivalent volumes. Neurological status was evaluated during and 24 h after middle cerebral artery occlusion. One day after middle cerebral artery occlusion, infarct volumes and brain edema were determined. In a separate group of animals, cortical perfusion was assessed by Laser-Doppler perfusion imaging. Albumin (1.25 g/kg; n = 3) or vehicle (sodium chloride 0.9%; n = 3) was administered at 2 h after onset of middle cerebral artery occlusion. Higher-dose albumin therapy (2.5 g/kg) significantly improved the neurological score compared to vehicle rats at 24 h, when administered at either 1 or 2 h after middle cerebral artery occlusion. Total infarct volume was reduced by albumin (2.5 g/kg given at 2 h) by 32% compared with vehicle-treated rats. Both albumin doses (1.25 and 2.5 g/kg) significantly reduced cortical and striatal infarct areas at several coronal levels when administered at 2 h after middle cerebral artery occlusion. Brain swelling was not affected by albumin treatment. Cortical perfusion declined during middle cerebral artery occlusion in both groups. Treatment with albumin led to 48% increases in cortical perfusion (P < 0.002), but saline caused no change. These results support a beneficial effect of albumin therapy in permanent focal cerebral ischemia.

Original languageEnglish
Pages (from-to)193-201
Number of pages9
JournalEuropean Journal of Pharmacology
Volume428
Issue number2
DOIs
StatePublished - Oct 5 2001

Fingerprint

Neuroprotective Agents
Brain Ischemia
Middle Cerebral Artery Infarction
Albumins
Perfusion
Brain Edema
Corpus Striatum
Perfusion Imaging
Nylons
Transient Ischemic Attack
Sodium Chloride
Sutures
Lysine
Sprague Dawley Rats
Lasers
Therapeutics

Keywords

  • (Rat)
  • Albumin
  • Imaging
  • Middle cerebral artery occlusion
  • Neuroprotection
  • Stroke

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Neuroprotective effect of treatment with human albumin in permanent focal cerebral ischemia : Histopathology and cortical perfusion studies. / Liu, Yitao; Belayev, Ludmila; Zhao, Weizhao; Busto, Raul; Belayev, Andrey; Ginsberg, Myron.

In: European Journal of Pharmacology, Vol. 428, No. 2, 05.10.2001, p. 193-201.

Research output: Contribution to journalArticle

@article{927d009b482344efaf733d459594c907,
title = "Neuroprotective effect of treatment with human albumin in permanent focal cerebral ischemia: Histopathology and cortical perfusion studies",
abstract = "In recent experimental studies, we demonstrated a highly beneficial neuroprotective effect of moderate- to high-dose human albumin treatment of transient focal cerebral ischemia, but we did not define the effect of albumin therapy in permanent focal cerebral ischemia. In this study, anesthetized Sprague-Dawley rats were subjected to permanent middle cerebral artery occlusion by retrograde insertion of an intraluminal nylon suture coated with poly-L-lysine. Albumin was administered i.v. at 2 h after onset of middle cerebral artery occlusion, in doses of either 1.25 (n = 8) or 2.5 g/kg (n = 6). In a separate group of animals, albumin (2.5 g/kg) was given 1 h after middle cerebral artery occlusion (n = 6). Vehicle-treated rats (n = 6) received 0.9{\%} saline in equivalent volumes. Neurological status was evaluated during and 24 h after middle cerebral artery occlusion. One day after middle cerebral artery occlusion, infarct volumes and brain edema were determined. In a separate group of animals, cortical perfusion was assessed by Laser-Doppler perfusion imaging. Albumin (1.25 g/kg; n = 3) or vehicle (sodium chloride 0.9{\%}; n = 3) was administered at 2 h after onset of middle cerebral artery occlusion. Higher-dose albumin therapy (2.5 g/kg) significantly improved the neurological score compared to vehicle rats at 24 h, when administered at either 1 or 2 h after middle cerebral artery occlusion. Total infarct volume was reduced by albumin (2.5 g/kg given at 2 h) by 32{\%} compared with vehicle-treated rats. Both albumin doses (1.25 and 2.5 g/kg) significantly reduced cortical and striatal infarct areas at several coronal levels when administered at 2 h after middle cerebral artery occlusion. Brain swelling was not affected by albumin treatment. Cortical perfusion declined during middle cerebral artery occlusion in both groups. Treatment with albumin led to 48{\%} increases in cortical perfusion (P < 0.002), but saline caused no change. These results support a beneficial effect of albumin therapy in permanent focal cerebral ischemia.",
keywords = "(Rat), Albumin, Imaging, Middle cerebral artery occlusion, Neuroprotection, Stroke",
author = "Yitao Liu and Ludmila Belayev and Weizhao Zhao and Raul Busto and Andrey Belayev and Myron Ginsberg",
year = "2001",
month = "10",
day = "5",
doi = "10.1016/S0014-2999(01)01255-9",
language = "English",
volume = "428",
pages = "193--201",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Neuroprotective effect of treatment with human albumin in permanent focal cerebral ischemia

T2 - Histopathology and cortical perfusion studies

AU - Liu, Yitao

AU - Belayev, Ludmila

AU - Zhao, Weizhao

AU - Busto, Raul

AU - Belayev, Andrey

AU - Ginsberg, Myron

PY - 2001/10/5

Y1 - 2001/10/5

N2 - In recent experimental studies, we demonstrated a highly beneficial neuroprotective effect of moderate- to high-dose human albumin treatment of transient focal cerebral ischemia, but we did not define the effect of albumin therapy in permanent focal cerebral ischemia. In this study, anesthetized Sprague-Dawley rats were subjected to permanent middle cerebral artery occlusion by retrograde insertion of an intraluminal nylon suture coated with poly-L-lysine. Albumin was administered i.v. at 2 h after onset of middle cerebral artery occlusion, in doses of either 1.25 (n = 8) or 2.5 g/kg (n = 6). In a separate group of animals, albumin (2.5 g/kg) was given 1 h after middle cerebral artery occlusion (n = 6). Vehicle-treated rats (n = 6) received 0.9% saline in equivalent volumes. Neurological status was evaluated during and 24 h after middle cerebral artery occlusion. One day after middle cerebral artery occlusion, infarct volumes and brain edema were determined. In a separate group of animals, cortical perfusion was assessed by Laser-Doppler perfusion imaging. Albumin (1.25 g/kg; n = 3) or vehicle (sodium chloride 0.9%; n = 3) was administered at 2 h after onset of middle cerebral artery occlusion. Higher-dose albumin therapy (2.5 g/kg) significantly improved the neurological score compared to vehicle rats at 24 h, when administered at either 1 or 2 h after middle cerebral artery occlusion. Total infarct volume was reduced by albumin (2.5 g/kg given at 2 h) by 32% compared with vehicle-treated rats. Both albumin doses (1.25 and 2.5 g/kg) significantly reduced cortical and striatal infarct areas at several coronal levels when administered at 2 h after middle cerebral artery occlusion. Brain swelling was not affected by albumin treatment. Cortical perfusion declined during middle cerebral artery occlusion in both groups. Treatment with albumin led to 48% increases in cortical perfusion (P < 0.002), but saline caused no change. These results support a beneficial effect of albumin therapy in permanent focal cerebral ischemia.

AB - In recent experimental studies, we demonstrated a highly beneficial neuroprotective effect of moderate- to high-dose human albumin treatment of transient focal cerebral ischemia, but we did not define the effect of albumin therapy in permanent focal cerebral ischemia. In this study, anesthetized Sprague-Dawley rats were subjected to permanent middle cerebral artery occlusion by retrograde insertion of an intraluminal nylon suture coated with poly-L-lysine. Albumin was administered i.v. at 2 h after onset of middle cerebral artery occlusion, in doses of either 1.25 (n = 8) or 2.5 g/kg (n = 6). In a separate group of animals, albumin (2.5 g/kg) was given 1 h after middle cerebral artery occlusion (n = 6). Vehicle-treated rats (n = 6) received 0.9% saline in equivalent volumes. Neurological status was evaluated during and 24 h after middle cerebral artery occlusion. One day after middle cerebral artery occlusion, infarct volumes and brain edema were determined. In a separate group of animals, cortical perfusion was assessed by Laser-Doppler perfusion imaging. Albumin (1.25 g/kg; n = 3) or vehicle (sodium chloride 0.9%; n = 3) was administered at 2 h after onset of middle cerebral artery occlusion. Higher-dose albumin therapy (2.5 g/kg) significantly improved the neurological score compared to vehicle rats at 24 h, when administered at either 1 or 2 h after middle cerebral artery occlusion. Total infarct volume was reduced by albumin (2.5 g/kg given at 2 h) by 32% compared with vehicle-treated rats. Both albumin doses (1.25 and 2.5 g/kg) significantly reduced cortical and striatal infarct areas at several coronal levels when administered at 2 h after middle cerebral artery occlusion. Brain swelling was not affected by albumin treatment. Cortical perfusion declined during middle cerebral artery occlusion in both groups. Treatment with albumin led to 48% increases in cortical perfusion (P < 0.002), but saline caused no change. These results support a beneficial effect of albumin therapy in permanent focal cerebral ischemia.

KW - (Rat)

KW - Albumin

KW - Imaging

KW - Middle cerebral artery occlusion

KW - Neuroprotection

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=0035812662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035812662&partnerID=8YFLogxK

U2 - 10.1016/S0014-2999(01)01255-9

DO - 10.1016/S0014-2999(01)01255-9

M3 - Article

C2 - 11675036

AN - SCOPUS:0035812662

VL - 428

SP - 193

EP - 201

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 2

ER -